Changes in Urinary Metal Levels After 660 nm Photobiomodulation in a Child Diagnosed with Autism Spectrum Disorder: A Case Study
By
Alex Zaharakis
Christian Bogner
June 23, 2026
Clinical Scorecard: Changes in Urinary Metal Levels After 660 nm Photobiomodulation in a Child Diagnosed with Autism Spectrum Disorder: A Case Study
At a Glance
Category Detail
Condition Autism Spectrum Disorder (ASD) Key Mechanisms Photobiomodulation (PBM) modulates mitochondrial cytochrome c oxidase activity and cellular bioenergetics. Target Population Children diagnosed with Autism Spectrum Disorder. Care Setting Clinical case study.
Key Highlights
Increased urinary aluminum levels observed after pulsed 660 nm PBM. Baseline urinary aluminum levels were stable before intervention. Mercury levels exceeded reference values in all specimens. Follow-up showed persistent elevated aluminum levels two months post-PBM. The study highlights the need for controlled studies on PBM effects. Guideline-Based Recommendations
Diagnosis
Monitor urinary metal levels in children with ASD. Management
Consider nonchelation strategies for heavy metal mobilization. Monitoring & Follow-up
Regular follow-up of urinary metal levels post-intervention. Risks
Chelation therapy carries risks including renal toxicity and metal redistribution. Patient & Prescribing Data
Pediatric patients with Autism Spectrum Disorder.
Pulsed 660 nm PBM may influence urinary metal excretion but requires further investigation.
Clinical Best Practices
Document baseline urinary metal levels before any intervention. Use validated methods for urinary metal analysis. Ensure informed consent for case studies and research. Related Resources & Content
